Cargando…
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
The development of resistance to cisplatin (DDP) occurs rapidly both in vitro and in vivo, and constitutes a major obstacle to effective therapy. We have previously demonstrated that there is a highly synergistic interaction between tamoxifen (TAM) and DDP against cell lines representative of three...
Autores principales: | McClay, E. F., Albright, K. D., Jones, J. A., Christen, R. D., Howell, S. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033375/ https://www.ncbi.nlm.nih.gov/pubmed/8080729 |
Ejemplares similares
-
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000) -
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
por: Jekunen, A. P., et al.
Publicado: (1994) -
Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005) -
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000) -
Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)